The global fondaparinux market is estimated to grow at a CAGR of nearly 7.5% during the forecast period. The major factors contributing to the market growth include the increasing number of hip and knee replacements and rising incidences of CVD. As per the Canadian Institute for Health Information (CIHI), the number of joint replacements grew over the past 5 years. Nearly 130,000 surgeries are performed annually in the country. During the period, 2017-2018, 70,502 knee replacements and 58,492 hip replacements were performed in Canada. This shows a rise of 17.0% and 17.4%, respectively, over the last 5 years.

In Canada, Ontario has the highest position and British Columbia held the second position for the total number of hip and knee replacement procedures performed in 2017-2018. This increase in hip and knee replacement procedures has been witnessed owing to the rising geriatric population in the country. Osteoarthritis condition grows with the age that usually requires a procedure. In 2019, there were 838,263 people ages 85 and over were living in Canada, which represents 2.2% of the total Canadian population. In addition, the number of people aged 85 and over rose by 19.4% during the period 2011-2016. This represents the rising life expectancy rate in the country, which is leading to increasing demand for joint replacement procedures in the country.

Fondaparinux is used for the prevention of a type of blood clot, referred to as deep vein thrombosis (DVT) in patients who are undergoing hip and knee replacement surgery and hip fracture surgery. DVT prevention may restrict the development of pulmonary embolism among these patients. Fondaparinux works similarly like heparin that blocks the activity of some clotting substances in the blood. This results in the emerging demand for these medications to prevent blood clots after hip and knee replacement procedures. Fondaparinux is considered as more efficient compared to low-molecular-weight heparin regarding post-administration side effects, including severe bleeding. Fondaparinux does not interact with platelets and has a longer half-life than heparin.

Market Segmentation

The global fondaparinux market is segmented based on product type, which is segmented into branded and generics. In 2019, Generics are estimated to hold the largest share in the market. Fondaparinux generic version of the Arixtra, anticoagulant drug, indicated to treat pulmonary embolism (PE) and DVT. It is also indicated to prevent DVT after major procedures.  Dr. Reddy Laboratories and Mylan N.V. offer a generic version of Arixtra (fondaparinux sodium) injection. As per the US FDA, in the US, 9 out of 10 prescriptions filled are for generic drugs. The rising availability of generic drugs creates competition among companies, which thereby results in making treatment more cost-effective and enhances access to healthcare for a large number of patients. This, in turn, is further encouraging the demand for generic fondaparinux.

Global Fondaparinux Market Share by Product Type, 2019 (%)

Regional Outlook

In 2019, North America is anticipated to hold the largest share in the market owing to the rising prevalence of osteoarthritis and deep vein thrombosis in the region. Osteoarthritis affects more than 32.5 million Us adults. In addition, the increasing prevalence of geriatric population is one of the major causes of the increasing prevalence of osteoarthritis. As per the Population Reference Bureau (PRB), the number of Americans aged 65 and over is estimated to nearly double from 52 million in 2018 to 95 million by 2060. The share of people aged 65-and-older in the total population will increase from 16% in 2018 to 23% by 2060. This, in turn, increases the need for joint replacement procedures that encourages the demand for fondaparinux to prevent blood clot after the procedure.

Global Fondaparinux Market Growth, by Region 2020-2026

Market Players Outlook 

The major players in the market include Mylan N.V., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Inc., Aurobindo Pharma Ltd., and Cadila Healthcare Ltd. (CHL). Product launches and mergers and acquisitions are considered as crucial strategies adopted by the market players to expand market share and gain a competitive advantage. For instance, in November 2018, Zydus Cadila has received the final approval from the USFDA to market Fondaparinux Sodium Injection USP, 2.5 mg/0.5 mL, 5 mg/0.4 mL 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose (US RLD – ARIXTRA). It will be produced at its manufacturing site of the partner. This will enable the company to generate significant revenue from the US. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global fondaparinux market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.